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Abstract
Background: Bone marrow sarcoidosis is extremely rare. The association between sarcoidosis and
lymphoproliferative disorders has been previously speculated, although the diagnosis of sarcoidosis often
precedes any hematological derangements.
Case presentation: Here, we report for the first time, a case of a 57-year-old Caucasian woman with a
previous diagnosis of monoclonal gammopathy of undetermined significance (MGUS) developing
hypercalcemia and renal failure with workup notable for isolated bone marrow sarcoidosis and not multiple
myeloma as expected. The patient was successfully managed with prednisone taper therapy with resolution of
her hypercalcemia and repeat bone marrow biopsies demonstrating resolving granulomas.
Conclusions: Our case illustrates the diagnostic challenges associated with bone marrow sarcoidosis and suggest
that chronic immune stimulation in the bone marrow in the setting of MGUS may be associated with the
development of localized sarcoidosis. The long term consequences of steroid therapy targeting sarcoidosis in this
patient with underlying MGUS remain unknown. Greater surveillance and closer followup is planned in light of the
increased risk of malignant transformation of MGUS into multiple myeloma in the setting of bone marrow
sarcoidosis.
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Background
Extrapulmonary manifestations of sarcoidosis are un-
common. Bone marrow sarcoidosis is infrequently
clinically encountered. In the few cases reported,
bone marrow involvement most often occurs in the
setting of systemic sarcoidosis [1–3]. Isolated bone
marrow sarcoidosis is exceedingly rare [4, 5]. The as-
sociation between sarcoidosis and malignant disease
including lymphoproliferative disorders has been pre-
viously explored [6, 7]. It has been postulated that
chronic immune stimulation associated with chronic
active sarcoidosis may lead to lymphoproliferative
disorders, termed the “sarcoid-lymphoma syndrome”
[7, 8]. In contrast to this temporal relationship, patients
with hematologic malignancies for more than a year
have been observed to develop sarcoidosis [9]. Herein,
we report an unusual case of a patient with four-year
history of monoclonal gammopathy of undetermined
significance (MGUS) preceding the diagnosis of isolated
bone marrow sarcoidosis presenting as hypercalcemia.
Case presentation
A 57-year-old Caucasian woman with a four-year
history of monoclonal gammopathy of undetermined
significance (MGUS) complained of several weeks of
dry mouth, polydipsia and episodes of confusion.
Her serum calcium was 14.4 mg/dL when tested at
the office of her primary care physician (PCP) and
sent to the emergency department (ED) where her
exam was remarkable only for dry mucous mem-
branes. Initial labs were notable for Ca 14.4 mg/dL,
albumin 5.0 g/dL, PTH 7 pg/mL, and Cr at 1.94.
CBC was notable for mild pancytopenia with WBC
3.5 (th/cmm) with normal differential, Hgb 11.7 g/
dL, Hct 34.2 (%), and PLT 145,000 (th/cmm). She
received a bolus of normal saline and was subse-
quently admitted to inpatient service. Initially, the
patient’s hypercalcemia was attributed to milk-alkali
syndrome and her calcium supplements were discon-
tinued. The patient was managed only with IV
hydration. The patient’s serum calcium trended down
to 10 mg/dL at the time of discharge.
There was a concern for a neoplastic process, particu-
larly myeloma, given her history of MGUS. The patient
underwent bone marrow biopsy at the time of discharge,
which was remarkable for non-necrotizing granulomas
with no findings suggestive of plasma cell dyscrasia or
other neoplasms. (Fig. 1a) Two weeks later, the patient’s
repeat calcium was 12.7 mg/dL despite adequate fluid
intake. The patient was admitted for further evaluation
of hypercalcemia and bone marrow granulomas. An
extensive hypercalcemia workup was unrevealing. Malig-
nant and infectious etiologies of granulomatous disease
in this patient were investigated. Results from repeat
SPEP, UPEP, and serum free light chains were unchanged
from baseline values. PTHrp was undetectable. PET scan
showed no FDG avid lesions. Infectious workup for
granulomas was negative. The patient’s hypercalcemia
was attributed to the granulomas given exclusion of
other potential causes. As a result, a workup for sarcoid-
osis was pursued, which was notable for elevated ACE
126 and urinary calcium of 256 mg/24 h (Table 1). Chest
X-ray and chest CT revealed no intrathoracic lymph-
adenopathy or pulmonary parenchymal findings (Fig. 2).
There was no evidence of sarcoidosis in any other organ.
The patient underwent a rapid prednisone taper over
9 days. After discontinuation of prednisone, she developed
hypercalcemia again. She was then treated with a slow
prednisone taper for four months with normalization of
serum calcium levels. A follow-up bone marrow biopsy
5 months later (1 month after 4-month course of slow
prednisone taper) showed partial resolution of granulomas
without malignancies. (Fig. 1b) At her follow-up PCP visit,
two years after her initial presentation, the patient was
overall asymptomatic with normal serum calcium, ACE,
and CBC.
Fig. 1 Bone marrow biopsies demonstrating non-necrotizing granulomas before steroid therapy (100× original magnification) (a) and follow-up
bone marrow biopsy 5 months after diagnosis (4 months later after steroid therapy) shows partial resolution of granulomas without evidence of
malignancy (200× original magnification) (b)
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Discussion
Bone marrow sarcoidosis is rare and previously
reported cases mostly involved patients with severe,
chronic, and widespread sarcoidosis. Bone marrow
biopsies are not routinely performed in the standard
workup of sarcoidosis, thus the overall incidence of
bone marrow involvement is unknown. One small
cohort study [5] estimated the bone marrow involve-
ment of patients with sarcoidosis to be 10 % with
most patients exhibiting hematologic abnormalities
as well as systemic sarcoidosis.
Our case illustrates the diagnostic challenges associated
with an atypical and rare manifestation of sarcoidosis. The
clinical presentation of bone marrow sarcoidosis is vari-
able, non-specific, and may overlap with those of systemic
sarcoidosis which include fever, fatigue, malaise, weight
loss, and night sweats. Patients with bone marrow involve-
ment may have associated hematological abnormalities in-
cluding anemia, leukopenia, and thrombocytopenia [3–5].
Although the diagnosis of sarcoidosis seemed unlikely
during the early workup of this patient, three lab abnor-
malities had some clinical utility and diagnostic value in
support of sarcoidosis: elevated ACE serum level, hyper-
calcemia, and hypercalciuria.. ACE levels are elevated in
75% of untreated patients with sarcoidosis and levels
tend to correlate with disease activity [10]. One study by
Ackermann et al. [11] estimates the prevalence of hyper-
calcemia in patients with sarcoidosis to be around 2 to
63 % depending on the population studied. The study
attributed the differences in prevalence of hypercalcemia
among sarcoidosis patients to the undulating course of
subacute sarcoidosis as well as variability in testing for
serum calcium. The study also found that hypercalciuria
appeared to be twice as prevalent as hypercalcemia and
argued that checking urine calcium should be part of the
workup of sarcoidosis.
Given the rare occurrence of bone marrow sarcoidosis,
there are currently no randomized controlled trials com-
paring treatment modalities. However, a review of the rele-
vant literature presents four case reports of patients with
biopsy-proven bone marrow sarcoidosis demonstrating
various approaches to treatment. One case report by Saliba
et al. [12] involved a 71-year-old. woman with severe
hypercalcemia and isolated BM sarcoidosis. The patient
was treated with IV saline hydration and her hypercalcemia
resolved after five days. The patient did not undergo
steroid therapy as her hypercalcemia did not reoccur.
Another case report by Slart et al. [13] involved a 49-
year-old man with lytic lesions and symptomatic
hypercalcemia found to have bone marrow sarcoidosis
and subacute pulmonary sarcoidosis. The patient
responded well to a steroid taper. A third case report
by del Mar Osma et al. [14] involved 44-year-old
woman with isolated bone marrow sarcoidosis
presenting with weakness, weight loss, and nightly
fevers. The patient was started on adalimumab with
subsequent resolution of her constitutional symptoms.
The final case report by Patel et al. [15] involved a 42-
year-old man with diabetes and systemic sarcoidosis with
bone marrow involvement presenting with anemia,








Ca (mg/dL) 14.3 12.7 8.5–10.5
iCa (mg/dL) 1.73 1.14–1.30
PTH (pg/mL) 7 5 10.0–60.0
Urine Ca – 256 mg/24 h Female: < 250 mg/24 h
1,25 OH Vit
D (ng/mL)
– 49 pg/mL –
25 OH Vit
D (ng/mL)
44 ng/mL – 25–80
PO4 (mg/dL) 5 2.5 2.6–4.5
Albumin (g/dL) 5 5 3.3–5.0
Creatinine 1.94 1.23 0.60–1.50
Fig. 2 Imaging Results: Normal Chest X-Ray (a) and Chest CT without evidence of intrathoracic lymphadenopathy or pulmonary parenchymal
lesions (b)
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thrombocytopenia, and splenomegaly. The patient was
initially treated with steroids, but discontinued due to
complications with his diabetes. The patient was treated
with adalimumab and his hematologic parameters
improved after two courses of therapy.
These case reports highlight that the therapeutic ap-
proach to patients with bone marrow sarcoidosis
depend on clinical presentation. Patients with symp-
tomatic hypercalcemia appear to respond well to IV
saline hydration and in severe cases may require
steroid taper therapy. Ackermann et al. [11] recom-
mended starting corticosteroid treatment if total
corrected calcium rises beyond 3 mmol/l (12 mg/dl)
or at lower levels if patients become symptomatic.
Patients with constitutional symptoms, systemic
sarcoidosis, or contraindications to steroid therapy
may respond better to management with adalimumab.
In our patient, IV saline therapy had minimal effects
on serum calcium. The patient was started on a rapid
steroid taper for 10 days with improvements in serum
calcium. Upon discontinuation of the steroids, the
patient’s hypercalcemia reoccurred. The patient was
managed with a second, but slow taper of steroids for
four months. The patient’s hypercalcemia and serum
ACE levels normalized and continue to remain stable.
An intriguing aspect of this case report involves the
potential relationship with the patient’s underlying
MGUS. The association between sarcoidosis and the
increased risk of malignancy particularly lymphoprolifer-
ative disorders has been previously examined [6–8] and
case reports with patients with sarcoidosis and MGUS
and multiple myeloma have been previously reported.
Likewise, it has been hypothesized that the risk of
multiple myeloma is increased in patients with sarcoid-
osis and a more rapid progression from MGUS to
multiple myeloma has been observed in the few cases
reported [14–16]. In virtually all of these cases, the diag-
nosis of sarcoidosis preceded or occurred concurrently
with that of MGUS. In our patient, the diagnosis of
sarcoidosis occurred four years after that of MGUS. It
may be possible that the patient developed subacute
bone marrow sarcoidosis years before her diagnosis of
MGUS, but only came to attention recently after
presenting with hypercalcemia. Alternatively, both
conditions may have developed concurrently, with her
bone marrow sarcoidosis remaining quiescent until her
hypercalcemia became clinically significant. Finally, our
patient’s case may represent a situation in which MGUS
preceded the development of sarcoidosis. Indeed, a
review of her CBC through the years including those
years prior to her admission when she was only diag-
nosed with MGUS would seem to reinforce this later
point. (Table 2) Previous CBCs were normal for multiple
preceding years and she only had pancytopenia on pres-
entation for admission with hypercalcemia secondary to
bone marrow isolated sarcoidosis.
Sarcoidosis has been observed to develop in patients
with hematologic malignancies with some investigators
attributing this to the use of immunosuppressive therapy
targeted at the underlying malignancy [17, 18]. Aside from
her known MGUS, our patient has never had any malig-
nant disease and was never treated with chemotherapy or
immunosuppressives. This raises the possibility that
MGUS, in addition to hematologic malignancies, may also
be a risk factor in the development of sarcoidosis. It may
be possible that the abnormal bone marrow milieu in this
patient with MGUS had an impact on the local develop-
ment of granulomas.
Conclusions
In conclusion, isolated bone marrow sarcoidosis is rare and
can be a diagnostic challenge. The clinical suspicion for
sarcoidosis should be raised in patients with underlying
hematologic disorders or malignancies. Due to the rarity of
the condition, long terms outcomes in such patients are
unclear. Surveillance and regular follow-up is planned in
view of the possibility of progression to multiple myeloma
or another lymphoproliferative disorder.





























HGB (g/dL) 13.7 14.1 12.3 11.7 11.5 10.4 12.8 13.5 12.0–16.0
HCT (%) 39.4 42 35.8 34.2 33.5 31 37.5 40.6 36.0–46.0
PLT (th/cmm) 198 225 193 145 210 198 157 188 150–400
WBC (th/cmm) 9.2 6 6.4 3.5 3.6 7.4 4.7 3.8 4.5–11.0
Poly (%) 79 60 – 61 62 94 83 57 40–70
Lymphs (%) 18 34 – 28 25 5 13 33 22–44
Monos (%) 3 4 – 10 11 1 3 8 4.0–11.0
Eos (%) 0 1 – 1 1 0 0 1 0–8
Basos (%) 0 1 – 0 1 0 1 1 0–3




Harvard Open-Access Publishing Equity (HOPE) fund for funding support of
article processing charge.
Availability of data and materials
All data is presented in main paper. Data sharing not applicable to this
article as no datasets were generated or analyzed during the current study.
Authors’ contributions
John Gubatan prepared case report and review of literature and drafted the
manuscript, John Vanderpool was the patient’s primary care physician,
obtained patient consent, and supervised in drafting of manuscript, Xiaohui
Wang was endocrinologist involved in the patient’s case and provided data
in Table 1, Abner Louissaint was pathologist involved in the patient’s case
and provided photos of bone marrow biopsies, Anuj Mahindra was
hematologist/oncologist involved in the patient’s case and provided
guidance in drafting manuscript. All authors interpreted the results and
contributed to critical review of the manuscript; John Gubatan had full
access to all of the data in the study and takes responsibility for the integrity
of the data.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Informed consent was obtained from the patient to report individual patient
data and for publication of this case report and any accompanying images.
A copy of the written consent is available for review by the Editor-in Chief of
this journal.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Medicine, Beth Israel Deaconess Medical Center and Harvard
Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. 2Hallmark
Health Medical Associates, Melrose-Wakefield Hospital, Reading, MA, USA.
3Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
4Division of Hematology and Oncology, University of California San Francisco
Medical Center, San Francisco, CA, USA. 5Department of Medicine,
Massachusetts General Hospital and Harvard Medical School, Boston, MA,
USA.
Received: 26 May 2016 Accepted: 6 September 2016
References
1. Baughman RP, et al. Clinical characteristics of patients in a case control
study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10):1885–9.
2. Browne PM, Sharma OP, Salkin D. Bone marrow sarcoidosis. JAMA.
1978;240(24):2654–5.
3. Patel Supen R. “Systemic sarcoidosis with bone marrow involvement
responding to therapy with adalimumab: a case report”. J Med Case
Reports. 2009;3:8573.
4. Adedayo AO, Grell GA, Bellot P. Severe refractory sarcoidosis in a 64-year-old
man with persistent leucopenia. West Indian Med J. 2003;52(1):56–8.
5. Yanardağ H, et al. Bone marrow involvement in sarcoidosis: an analysis of
50 bone marrow samples. Haematologia. 2002;32(4):419.
6. Brincker H. Coexistence of sarcoidosis and malignant disease: causality or
coincidence? Sarcoidosis. 1989;6(1):31.
7. Goswami T, et al. The sarcoid-lymphoma syndrome. Clin Lymphoma
Myeloma Leuk. 2010;10(4):241–7.
8. Saad T, Agmon-Levin N, Shoenfeld Y. Chronic stimulation of the immune
system in sarcoidosis and monoclonal gammopathy of undetermined
significance]. Harefuah. 2009;148(12):809.
9. Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol.
2007;25(3):326–33.
10. Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis–its
value in present clinical practice. Ann Clin Biochem. 1989;26:13–8.
11. Ackermann D. Hypercalcemia in sarcoidosis–case report, prevalence,
pathophysiology and therapeutic options]. Therapeutische Umschau Revue
thérapeutique. 2007;64(5):281.
12. Saliba A, Walid R, Elias MS. Recurrent severe hypercalcemia caused by bone
marrow sarcoidosis. Am J Med Sci. 2005;330(3):147–9.
13. Slart RM, et al. Lytic skull lesions and symptomatic hypercalcaemia in bone
marrow sarcoidosis. J Intern Med. 1999;246(1):117–20.
14. Del Mar Osma M, Francisco Jose O. “Marrow noncaseating granulomas:
sarcoidosis”. Blood. 2012;119(7):1622.
15. Sharma AM, Fried J, Sharma OP. “Monoclonal gammopathy of
undetermined significance in sarcoidosis. Two case reports’. Sarcoidosis.
1992;9(1):70.
16. Sen F, Mann KP, Jeffrey Medeiros L. “Multiple myeloma in association with
sarcoidosis: a case report and review of the literature.”. Arch Pathol Lab
Med. 2002;126(3):365–8.
17. Merchant TE, Filippat DA, Yahalom J. Sarcoidosis following chemotherapy
for Hodgkin’s disease. Leukemia & lymphoma. 1994;13(3–4):339–47.
18. Haran MZ, Feldberg E, Berrebi A. Lymphoma masking sarcoidosis. Leukemia
& lymphoma. 2002;43(8):1709–10.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gubatan et al. Biomarker Research  (2016) 4:18 Page 5 of 5
